Lysosomal-associated protein transmembrane-4 beta: a novel potential biomarker for cancer therapy with multiple functions  

作　　者：Xi-Chao Xu Jian-Guo Feng Li-Ling Tang 

机构地区：[1]Key Laboratory of Biorheological Science and Technology,Ministry of Education,College of Bioengineering,Chongqing University,Chongqing 400044,China [2]Department of Anesthesiology,The Affiliated Hospital of Southwest Medical University,Luzhou,Sichuan 646000,China

出　　处：《Chinese Medical Journal》2021年第1期38-40,共3页中华医学杂志（英文版）

基　　金：supported by the grants from the Natural Science Foundation of China(No.31670952);the Fundamental Research Funds for the Central Universities(No.106112017CDJXSYY0001);Graduate Research and Innovation Foundation of Chongqing(No.CYB19043)。

摘　　要：LAPTM4B,which is a proto-oncogene,plays important roles in cancer progression,including clinical stages and pathologic grades.[1]The LAPTM4B gene encodes the lysosomal-associated protein transmembrane-4 beta(LAPTM4B)protein and LAPTM4B is cloned from hepatocellular carcinoma(HCC).[2]There is increasing evidence that LAPTM4B is a novel oncogene,which is over-expressed in many human solid tumors.[3]Furthermore,the up-regulation of LAPTM4B is associated with chemotherapy resistance,as well as poor clinical outcomes and prognoses.[4,5]LAPTM4B also promotes cell survival,growth,proliferation,metastasis,tolerance to metabolic stress,and autophagy.[6]Thus,the LAPTM4B protein may represent an excellent candidate for individualized treatment and tumor monitoring.

关 键 词：cancer clinical CHEMOTHERAPY 

分 类 号：R730.5[医药卫生—肿瘤]